

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

MOLM-16

RRID:CVCL_2120

Type: Cell Line

Proper Citation

RRID:CVCL_2120

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2120

Proper Citation: RRID:CVCL_2120

Description: Cell line MOLM-16 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adult acute myeloid leukemia with minimal differentiation

Defining Citation: [PMID:12526922](#), [PMID:16408098](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MOLM-16

Synonyms: MOLM16

Cross References: BTO:BTO_0004176, EFO:EFO_0006652, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473252, BioSample:SAMN10989567, cancercellines:CVCL_2120, Cell_Model_Passport:SIDM00435, ChEMBL-Cells:ChEMBL4879543, Cosmic:787457, Cosmic:975275, Cosmic:1012096, Cosmic:1281334, Cosmic:2131560, Cosmic:2306221, Cosmic:2750865, Cosmic-CLP:1330948, DepMap:ACH-000369, DSMZ:ACC-555, DSMZCellDive:ACC-555, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1330948, GEO:GSM887330, GEO:GSM888406,

GEO:GSM1374690, GEO:GSM1446739, IARC_TP53:28318, JCRB:JCRB1815, LiGeA:CCLE_524, PharmacDB:MOLM16_951_2019, PRIDE:PXD030304, Progenetix:CVCL_2120, Wikidata:Q54906324

ID: CVCL_2120

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260913T004916+0000

Ratings and Alerts

No rating or validation information has been found for MOLM-16.

No alerts have been found for MOLM-16.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Schäfer S, et al. (2026) ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia. Cell reports, 45(3), 117010.

Román-Trufero M, et al. (2026) A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1846.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Bai L, et al. (2019) A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer cell, 36(5), 498.